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Investigation of the Potential for Binding of
Di(2-ethylhexyl) Phthalate (DEHP) to Rat
Liver DNA in Vivo
by Werner K. Lutz*
It was the aim of this investigation to determine whether or not covalent binding of di(2-ethylhexyl)
phthalate (DEHP) to rat liver DNA could be a mechanism of action contributing to the observed induction
of liver tumors after lifetime feeding of rodents with high doses of DEHP. DEHP radiolabeled in different
positions was administered orally to female F344 rats with or without pretreatment for 4 weeks with 1%
unlabeledDEHPinthediet. LiverDNAwasisolatedafter 16hrandanalyzedforradioactivity. Administration
of[14C]carboxylate-labeled DEHPresulted in no measurable DNAradioactivity. With DEHP["4C]- and [3H]-
labeled in the alcohol moiety as well as with 2-ethyl[1-14C]hexanol, radioactivity was clearly measurable in
the DNA. HPLC analysis of enzyme-degraded DNA revealed that the normal nucleosides had incorporated
radiolabel whereas no radioactivity was detectable in those fractions where the carcinogen-modified nucleo-
side adducts are expected. Aquantitative evaluation ofthe negative data in terms ofa limit ofdetection for
a covalent binding index (CBI) indicates that covalent interaction with DNA is highly unlikely to be the
mode oftumorigenic action of DEHP in rodents.
Introduction
Covalent binding of reactive metabolites of organic
chemicals to DNAin the target cell is an important early
event in the carcinogenicity of a large number ofcarcin-
ogens. This interaction can have a number ofmutational
consequences so that many short-term tests on muta-
genicity can be used for a qualitative screening ofchem-
icals for DNA interactions. The amount of carcinogen
bound to DNA is dependent on a variety of parameters,
such as the concentration at the site ofmetabolism, the
rate of enzymatic activation and of enzymatic and no-
nenzymatic inactivation reactions, the diffusion to the
critical DNA target, and the reactivity towards nucleic
acids as opposed to other nucleophiles. Because of the
complexity ofthese in part competing processes, only an
in vivo situation is appropriate for a quantitative eval-
uation ofthe DNA damage in an attempt to estimate the
carcinogenicpotencyofachemicalknowntobindtoDNA.
The binding of a test compound to DNA in vivo has
been determined with the use of radiolabeled markers
for about 100 chemicals (1). With the introduction (2) of
thecovalentbindingindex [CBI = (,umolechemicalbound
per mole DNA nucleotides)/(mmole chemical adminis-
tered per kilogram body weight)] to normalize the DNA
damage to the dose administered, a correlation of car-
cinogenic potency with CBI became possible and showed
that a CBI of 104 to 103 can form the basis for a potent
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carcinogenicity, while a CBI of around 100 is found with
moderate carcinogens and of1 to 10 forweak carcinogens
(3). This correlation also means that chemicals with a
CBI ofless than 0.1 are highly unlikely to give rise to a
carcinogenicity detectable in along-term bioassay unless
they have, in addition to a minute DNA binding activity,
some cocarcinogenic or promoting activity (4).
The possibility for such a distinction between DNA
binding on the one hand and other mechanisms on the
other hand in the process of tumor formation was the
reasonfortheinterestinperformingDNA-bindingassays
in vivo with compounds which gave rise to an increased
tumor incidence in a rodent bioassay. The idea behind it
was theunderstandingthatan extrapolation to lowdoses
to which man is exposed will be linear for the formation
of DNA-carcinogen adducts, while nonlinearities and
possibly thresholds could be expected for the low-dose
extrapolations withothermechanisms ofcarcinogenic ac-
tion.
Withthe use ofradiolabeled testcompound for a DNA-
binding study, only those nucleotide-carcinogen adducts
are detectable which still carry the radiolabel. Since
DEHP is composed of essentially two structural ele-
ments, the phthalic acid and the alcohol, differently
marked DEHP molecules (I-IV) were used (Fig. 1).
The long-term exposure to DEHP used in the carcin-
ogenicity studies could have induced qualitative and/or
quantitative changes in the enzymatic drug metabolism
pattern. In order to investigate whether such pretreat-








FIGURE 1. Chemical structures of test compounds: (I, II, III) di(2-
ethylhexyl) phthalate (DEHP); (IV) 2-ethylhexanol (EH); (*) de-
notes 14C; (T) denotes 'H.
animalswaspretreatedfor4weekswithadietcontaining
10 g/kg DEHP (1%).
Methods and Materials
A detailed report on this study has recently been pub-
lished (5). The following is only a briefoverview.
Female F344 rats were from Charles River (Wiga,
Sulzfeld, FRG) and weighed between 182 and 199 g at
the time oftreatment with the radiolabeled compounds.
Duplicate animals were used for all experiments. DEHP
was administered byoralgavage in olive oil onachemical
dose level of500 mg/kg. The radiolabel dose was 10 mCi/
kg [14C]DEHP (I). DEHP II and III were administered
together at 5 mCi [14C] plus 40 mCi [3H] per kg body
weight. 2-Ethyl[1-14C]hexanol (EH IV) was given on a
dose level of50 mg (about 14 mCi)/kg. The animals were
placedinall-glassmetabolismcages, andthecarbondiox-
ide expired was collected for a determination ofthe met-
abolic stability ofthe [14C]-label administered. After 16
hr, the animals were killed with ether, the liver was ex-
cised and homogenized immediately, and a crude chro-
matin fraction was prepared. DNA was purified by ex-
tractions of the chromatin, hydroxyapatite adsorption
chromatography, dialysis, andprecipitationwithethanol.
DNAwas degraded with DNAase, phosphodiesterase,
and alkaline phosphatase to the deoxyribonucleosides, or
with hydrochloric acid to the purine bases and apurinic
acid. Separation ofthe DNA constituents was performed
with reverse-phase HPLC.
Thespecificactivitiesdetermined fortheDNAsamples
were expressed inthe units ofthe covalent bindingindex
(CBI), in order to allow a quantitative comparison with




I, a minute amount ofradioactivity could be detected in
only one out of four DNA samples. In all other samples,
irrespective ofthe DEHP pretreatment, the radioactiv-
ity was below the limit of detection ofthe order of 0.02
CBI units. When the label was in the alcohol moiety
(DEHP II and III), DNA radioactivity was easily de-
tected in all cases, regardless ofwhether the label was
14C or 3H. Pretreatment with DEHP had no influence
on total radioactivity in DNA after oral administration
of either label. Apparent binding indices of 3 and 0.5
were calculated for the [14C]- and [3H]-labels, respec-
tively. After administration of [14C]EH IV, the radioac-
tivity in the DNA was about twice the respective value
obtained from [14C]DEHP II administration, and appar-
ent binding indices ofabout 6 resulted. This higher spe-
cific activity ofDNA was accompanied by a higher frac-
tion ofthe radioactivity dose expired in the form ofC02.
Analysis of Nucleosides
An analysis of deoxyribonucleosides was carried out
withthe DNAobtained fromratstreated with[14C]- and
[3H]-labeled DEHP(II and III) and[14C]-labeled EH IV.
It could be shown that the normal nucleosides were ra-
diolabeled, whereas noradiolabel was detectable inthose
fractions which nornally contain the more lipophilic
DNA-carcinogen adducts. After deduction of this ana-
bolic incorporation ofradiolabel from the original (total)
specific activity of DNA, maximum possible CBI values
of0.1 to 0.5 and 0.6 to 0.9 resulted for DEHP II and EH
IV, respectively, while the tritium data from DEHP III
gave an upper bound of0.2 to 0.3 for true covalent bind-
ing.
Another way of estimating maximum possible CBI
could be based upon the general assumption that carcin-
ogen-deoxyribonucleoside adducts are expected to elute
afterthe normalconstituents due to ahigherlipophilicity
of such adducts. No radioactivity could be detected in
this region. On the basis ofthe standard deviation ofthe
backgroundradioactivitydeterminedfromaDNAsample
isolated from an untreated animal, a limit of detection
forapossiblecarcinogen-deoxyribonucleoside adductwas
calculated. The maximum CBI ofDEHP then was below
0.07for[14C]DEHP II, below0.04for[3H]DEHP III and
below 0.03 for [14C]EH IV
Analysis of Purines
The above discussion is based upon the general knowl-
edge that nucleoside adducts oftypical genotoxic carcin-
ogens such as benzo(a)pyrene, 7,12-dimethyl-
benz(a)anthracene, or 3-methylcholanthrene elute after
the natural nucleosides, due to increased lipophilicity. It
is possible that smaller adducts such as methylated or
ethylated nucleosideswould notelutemuchlaterthanthe
parent natural nucleoside. Therefore, a purine base
analysis was performed after acidhydrolysis oftwo DNA
samples oftwo animals treated with DEHP II plus III,
one each with and without DEHP pretreatment. The
HPLC system chosen was known to separate 7-methyl-
or7-ethylguanine, themostabundantalkylationproducts
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in DNA, from their parent base. No radioactivity was
detectable at elution volumes known for methylated or
ethylated products. A limit of detection of CBI < 0.05
and < 0.09 resulted for [14C]DEHP II and CBI < 0.03
and < 0.05resulted for[3H]DEHP III, with and without
DEHP pretreatment, respectively.
Discussion
The results show that a covalent binding of DEHP to
rat liver DNA must be below a CBI value of 0.05. This
upperboundis200,000timesbelowtheCBIforthepotent
hepatocarcinogen aflatoxin B1 and 20 to 200 times below
the CBI ofweakly DNA-binding carcinogens, where very
large daily doses are required to produce an increase in
tumor-bearing animals in a standard long-term bioassay.
The negative binding data derived from these exper-
iments with DEHP therefore suggest that the tumori-
genicity ofthis compound was probably due to a mode of
action not related to DNA binding. In such a situation,
tumor induction could go in parallel with some type of
biological response-possibly species specific-which
might also be observable in the long-term bioassay. Most
of these biological responses are expected to follow the
sigmoid dose-effect relationship generally known from
other pharmacological activities. Such a mechanism
mighttherefore allowthe consideration ofathreshold and
it will be most important to search for other effects of
DEHP on the animals' biology and find out whether the
processes which parallel the induction of tumors in the
bioassay are also found in humans exposed tomuch lower
doses.
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